Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Baker Bros. Advisors Dump 75% Of Stake In XOMA Corp (XOMA) after Late-Stage Study Failure

Was Baker Bros. Advisors‘ investment in XOMA Corp (NASDAQ:XOMA) a mistake? According to a recent filing with the Securities and Exchange Commission, the fund has dumped 78% of its stake in the company. Around 11 million shares were sold at a price of $1.09 each, leaving Baker Bros. Advisors with a holding of 3.71 million shares. Was Julian and Felix Baker‘s decision to limit exposure to the company dictated by one of XOMA’s drug failing in a late-stage study?!

Felix Baker - Baker Bros.

Julian Baker And Felix Baker
Julian Baker And Felix Baker
Baker Bros. Advisors

First a quick word on why we track hedge fund activity. In 2014, equity hedge funds returned just 1.4%. In 2013, that figure was 11.3%, and in 2012, they returned just 4.8%. These are embarrassingly low figures compared to the S&P 500 ETF (SPY)’s 13.5% gain in 2014, 32.3% gain in 2013, and 16% gain in 2012. Does this mean that hedge fund managers are dumber than a bucket of rocks when it comes to picking stocks? The answer is definitely no. Our small-cap hedge fund strategy, which identifies the best small-cap stock picks of the best hedge fund managers returned 28.2% in 2014, 53.2% in 2013, and 33.3% in 2012, outperforming the market each year (it’s outperforming it so far in 2015 too). What’s the reason for this discrepancy you may ask? The reason is simple: size. Hedge funds have gotten so large, they have to allocate the majority of their money into large-cap liquid stocks that are more efficiently priced. They are like mutual funds now.

Consider Ray Dalio’s Bridgewater Associates, the largest in the industry with about $165 billion in AUM. It can’t allocate too much money into a small-cap stock as merely obtaining 2% exposure would really move the price. In fact, Dalio can’t even obtain 2% exposure to many small-cap stocks, even if he essentially owned the entire company, as they’re simply too small (or rather, his fund is too big). This is where we come in. Our research has shown that it is actually hedge funds’ small-cap picks that are their best performing ones and we have consistently identified the best picks of the best managers, returning 144% since the launch of our small-cap strategy compared to less than 60% for the S&P 500 (see more details).

As stated above, an eye drug developed by XOMA Corp (NASDAQ:XOMA) failed a late-stage study, according to a report by the Wall Street Journal. The drug in question, named Gevokizumab, was developed with the aim of treating Behçet’s disease uveitis, a severe form of uveitis, a chronic inflammation of eye blood vessels. As a result, the stock plummeted from $4.39 at the end of the trading session on July 21 to $0.85 the next day, before staging a comeback to the $1 level. Based in Berkeley, CA, XOMA Corp has a market cap of $116 million and does not pay dividends. For the first quarter of 2015, the company posted revenues of $2.65 million, 22% lower than a year earlier, and a loss per share of $0.19. Current quarter is expected to bring revenues of $4.38 million and a loss of $0.18 per share.

Among the hedge funds we track, the most prominent holders of XOMA shares are  Mark Kingdon‘s Kingdon Capital and David Shaw‘s D E Shaw, which own 7.57 million and 1.94 million shares respectively.

As biotech stocks are the bread and butter of the Felix brothers, Baker Bros. Advisors has most of its porftolio invested in the healthcare sector. Among the fund’s top holdings are Pharmacyclics, Inc. (NASDAQ:PCYC), up 110% since January, and Incyte Corporation (NASDAQ:INCY), which has appreciated by 53% so far this year. Baker Bros. Advisors has recently hit the jack pot with Anacor Pharmaceuticals Inc (NASDAQ:ANAC), after the company’s Crisaborole ointment passed late-stage studies with flying colors. As a result, the stock had rocketed by 65% to $140 per share, before further advancing to $149 per share as of the time of this writing. Baker Bros. Advisors holds some 4.2 million shares of Anacor.

Disclosure: none.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!